论文部分内容阅读
HCV affects 170 million people, but there are no vaccines in routine clinical use.Development of effective vaccine against HCV that elicit robust long-term T cellular immune response is required to prevent HCV infection in populations.Here we developed various DNA vaccine candidates and recombinant vaccinia TianTan strain (rVTT) viruses, which expressing glycoprotein E1/E2 of hepatitis C virus (HCV) derived from Chinese (1 b subtype); In this investigation, we have characterized the systemic immune responses in BALB/c mice using various DNA and rVTT vaccine candidates against HCV; we designated these several kinds of DNA vaccine candidates the priming vaccination by i.m..After 16 weeks, some groups of mice were boosted by s.c.with 1 × 106 PFU rVTT (referred to below as DNA/rVTT).